These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

627 related items for PubMed ID: 11163499

  • 1. Phase III trial of accelerated hyperfractionation with or without difluromethylornithine (DFMO) versus standard fractionated radiotherapy with or without DFMO for newly diagnosed patients with glioblastoma multiforme.
    Prados MD, Wara WM, Sneed PK, McDermott M, Chang SM, Rabbitt J, Page M, Malec M, Davis RL, Gutin PH, Lamborn K, Wilson CB, Phillips TL, Larson DA.
    Int J Radiat Oncol Biol Phys; 2001 Jan 01; 49(1):71-7. PubMed ID: 11163499
    [Abstract] [Full Text] [Related]

  • 2. Hypofractionated accelerated radiotherapy (HART) with concurrent and adjuvant temozolomide in newly diagnosed glioblastoma: a phase II randomized trial (HART-GBM trial).
    Mallick S, Kunhiparambath H, Gupta S, Benson R, Sharma S, Laviraj MA, Upadhyay AD, Julka PK, Sharma D, Rath GK.
    J Neurooncol; 2018 Oct 01; 140(1):75-82. PubMed ID: 29936695
    [Abstract] [Full Text] [Related]

  • 3. Phase III randomized study of postradiotherapy chemotherapy with alpha-difluoromethylornithine-procarbazine, N-(2-chloroethyl)-N'-cyclohexyl-N-nitrosurea, vincristine (DFMO-PCV) versus PCV for glioblastoma multiforme.
    Levin VA, Uhm JH, Jaeckle KA, Choucair A, Flynn PJ, Yung WKA, Prados MD, Bruner JM, Chang SM, Kyritsis AP, Gleason MJ, Hess KR.
    Clin Cancer Res; 2000 Oct 01; 6(10):3878-84. PubMed ID: 11051233
    [Abstract] [Full Text] [Related]

  • 4. Survival results from a phase I study of etanidazole (SR2508) and radiotherapy in patients with malignant glioma.
    Chang EL, Loeffler JS, Riese NE, Wen PY, Alexander E, Black PM, Coleman CN.
    Int J Radiat Oncol Biol Phys; 1998 Jan 01; 40(1):65-70. PubMed ID: 9422559
    [Abstract] [Full Text] [Related]

  • 5. Hypo-fractionated IMRT for patients with newly diagnosed glioblastoma multiforme: a 6 year single institutional experience.
    Ciammella P, Galeandro M, D'Abbiero N, Podgornii A, Pisanello A, Botti A, Cagni E, Iori M, Iotti C.
    Clin Neurol Neurosurg; 2013 Sep 01; 115(9):1609-14. PubMed ID: 23453151
    [Abstract] [Full Text] [Related]

  • 6. Phase II, two-arm RTOG trial (94-11) of bischloroethyl-nitrosourea plus accelerated hyperfractionated radiotherapy (64.0 or 70.4 Gy) based on tumor volume (> 20 or < or = 20 cm(2), respectively) in the treatment of newly-diagnosed radiosurgery-ineligible glioblastoma multiforme patients.
    Coughlin C, Scott C, Langer C, Coia L, Curran W, Rubin P.
    Int J Radiat Oncol Biol Phys; 2000 Dec 01; 48(5):1351-8. PubMed ID: 11121633
    [Abstract] [Full Text] [Related]

  • 7. Phase II study of accelerated fractionation radiation therapy with carboplatin followed by vincristine chemotherapy for the treatment of glioblastoma multiforme.
    Levin VA, Maor MH, Thall PF, Yung WK, Bruner J, Sawaya R, Kyritsis AP, Leeds N, Woo S, Rodriguez L.
    Int J Radiat Oncol Biol Phys; 1995 Sep 30; 33(2):357-64. PubMed ID: 7673023
    [Abstract] [Full Text] [Related]

  • 8. Radiation therapy and hydroxyurea followed by the combination of 6-thioguanine and BCNU for the treatment of primary malignant brain tumors.
    Prados MD, Larson DA, Lamborn K, McDermott MW, Sneed PK, Wara WM, Chang SM, Mack EE, Krouwer HG, Chandler KL, Warnick RE, Davis RL, Rabbitt JE, Malec M, Levin VA, Gutin PH, Phillips TL, Wilson CB.
    Int J Radiat Oncol Biol Phys; 1998 Jan 01; 40(1):57-63. PubMed ID: 9422558
    [Abstract] [Full Text] [Related]

  • 9. Role of adjuvant or salvage radiosurgery in the management of unresected residual or progressive glioblastoma multiforme in the pre-bevacizumab era.
    Niranjan A, Kano H, Iyer A, Kondziolka D, Flickinger JC, Lunsford LD.
    J Neurosurg; 2015 Apr 01; 122(4):757-65. PubMed ID: 25594327
    [Abstract] [Full Text] [Related]

  • 10. Hyperfractionated and accelerated-hyperfractionated radiotherapy for glioblastoma multiforme.
    Nieder C, Nestle U, Ketter R, Kolles H, Gentner SJ, Steudel WI, Schnabel K.
    Radiat Oncol Investig; 1999 Apr 01; 7(1):36-41. PubMed ID: 10030622
    [Abstract] [Full Text] [Related]

  • 11. A randomized phase III study of accelerated hyperfractionation versus standard in patients with unresected brain metastases: a report of the Radiation Therapy Oncology Group (RTOG) 9104.
    Murray KJ, Scott C, Greenberg HM, Emami B, Seider M, Vora NL, Olson C, Whitton A, Movsas B, Curran W.
    Int J Radiat Oncol Biol Phys; 1997 Oct 01; 39(3):571-4. PubMed ID: 9336134
    [Abstract] [Full Text] [Related]

  • 12. Radiation therapy dose escalation for glioblastoma multiforme in the era of temozolomide.
    Badiyan SN, Markovina S, Simpson JR, Robinson CG, DeWees T, Tran DD, Linette G, Jalalizadeh R, Dacey R, Rich KM, Chicoine MR, Dowling JL, Leuthardt EC, Zipfel GJ, Kim AH, Huang J.
    Int J Radiat Oncol Biol Phys; 2014 Nov 15; 90(4):877-85. PubMed ID: 25257812
    [Abstract] [Full Text] [Related]

  • 13. Hyperfractionated radiation therapy and bis-chlorethyl nitrosourea in the treatment of malignant glioma--possible advantage observed at 72.0 Gy in 1.2 Gy B.I.D. fractions: report of the Radiation Therapy Oncology Group Protocol 8302.
    Nelson DF, Curran WJ, Scott C, Nelson JS, Weinstein AS, Ahmad K, Constine LS, Murray K, Powlis WD, Mohiuddin M.
    Int J Radiat Oncol Biol Phys; 1993 Jan 15; 25(2):193-207. PubMed ID: 8380567
    [Abstract] [Full Text] [Related]

  • 14. Encouraging experience of concomitant Temozolomide with radiotherapy followed by adjuvant Temozolomide in newly diagnosed glioblastoma multiforme: single institution experience.
    Jalali R, Basu A, Gupta T, Munshi A, Menon H, Sarin R, Goel A.
    Br J Neurosurg; 2007 Dec 15; 21(6):583-7. PubMed ID: 18071985
    [Abstract] [Full Text] [Related]

  • 15. Randomized phase I/II trial of two variants of accelerated fractionated radiotherapy regimens for advanced head and neck cancer: results of RTOG 88-09.
    Fu KK, Clery M, Ang KK, Byhardt RW, Maor MH, Beitler JJ.
    Int J Radiat Oncol Biol Phys; 1995 Jun 15; 32(3):589-97. PubMed ID: 7790243
    [Abstract] [Full Text] [Related]

  • 16. The role of radiation therapy in treatment of adults with newly diagnosed glioblastoma multiforme: a systematic review and evidence-based clinical practice guideline update.
    Ziu M, Kim BYS, Jiang W, Ryken T, Olson JJ.
    J Neurooncol; 2020 Nov 15; 150(2):215-267. PubMed ID: 33215344
    [Abstract] [Full Text] [Related]

  • 17. Postoperative radiotherapy of glioblastoma multiforme: analysis and critical assessment of different treatment strategies and predictive factors.
    Piroth MD, Gagel B, Pinkawa M, Stanzel S, Asadpour B, Eble MJ.
    Strahlenther Onkol; 2007 Dec 15; 183(12):695-702. PubMed ID: 18040615
    [Abstract] [Full Text] [Related]

  • 18. External beam radiation dose escalation for high grade glioma.
    Khan L, Soliman H, Sahgal A, Perry J, Xu W, Tsao MN.
    Cochrane Database Syst Rev; 2020 May 21; 5(5):CD011475. PubMed ID: 32437039
    [Abstract] [Full Text] [Related]

  • 19. Phase I/IIa trial of fractionated radiotherapy, temozolomide, and autologous formalin-fixed tumor vaccine for newly diagnosed glioblastoma.
    Ishikawa E, Muragaki Y, Yamamoto T, Maruyama T, Tsuboi K, Ikuta S, Hashimoto K, Uemae Y, Ishihara T, Matsuda M, Matsutani M, Karasawa K, Nakazato Y, Abe T, Ohno T, Matsumura A.
    J Neurosurg; 2014 Sep 21; 121(3):543-53. PubMed ID: 24995786
    [Abstract] [Full Text] [Related]

  • 20. Acute toxicity and changes in quality of life during a combined radio-chemotherapy of glioblastomas with topotecan (Hycamtin).
    Gross MW, Altscher R, Brandtner M, Häusser-Mischlich H, Kiricuta IC, Siegmann AD, Engenhart-Cabillic R.
    Strahlenther Onkol; 2001 Dec 21; 177(12):656-61. PubMed ID: 11789404
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 32.